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AntioxidantAbstract Azide–alkyne cycloaddition was attempted to generate a flavanone hesperetin based phe-
nyl substituted 1,2,3-triazolyls as semi-synthetic natural product derivatives utilizing copper-
catalyzed click chemistry. All final compounds were analyzed for their in vitro antioxidant abilities
using DPPH and ABTS bioassay. Moreover, cancerous cell inhibitory prospect of titled compounds
was screened against cervical cancer cell lines, HeLa and CaSki and an ovarian cancer cell line SK-
OV-3 implementing SRB assay. Bearable toxicity of 6a-s was examined employing Madin–Darby
canine kidney (MDCK) non-cancer cell line. Overall, 6a-s indicated remarkable antioxidant power
in scavenging DPPH and ABTS+; particularly, an analog 6o with meta-methoxy substituent
showed most potent radical scavenging activity, whereas scaffolds 6d with para-fluoro, 6k with
ortho-methyl, and 6o with meta-methoxy performed excellently in inhibiting both the cervical cancer
cell lines and analog 6q with meta-trifluoromethyl substituent expressed excellent sensitivity toward
ovarian cancer cell line. From the structure–activity point of view, nature and position of the elec-
tron withdrawing and electron donating functional groups on the phenyl ring attached to the tria-
158 B. Mistry et al.zole core may contribute to the anticipated antioxidant and anticancer action. Structure of final
compounds was adequately confirmed exploring different spectroscopic techniques and elemental
analysis in addition to the measurements of some physical properties.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
ROS, reactive oxygen species carrying unpaired electrons are
highly reactive molecules, for example superoxide (O2
),
hydroxyl (HO), peroxyl (ROO), alkoxyl (RO), and nitric
oxide (NO) radicals capable of rapidly bind the molecules in
adjacent cells. Cellular metabolism processes yield ROS and
their access amount results into the damage of essential com-
ponents of cells such as DNA, lipids and proteins which lead
to the occurrence of diseases such as neurological disorders,
hypertension, cancer, and diabetes (Weidinger and Kozlov,
2015). This oxidative damage to different kinds of biomole-
cules is referred to as ‘‘oxidative stress”. Oxidative stress is
regarded to considerably promote the growth of a number of
illnesses, particularly age-related diseases (Schieber and
Chandel, 2014). Oxidation process is known as a substance
response that exchanges hydrogen atom or electrons from a
material to an oxidizing agent. The description of antioxidant
is initially relevant to elements that avoid the intake of oxygen
by human tissues. In other terms, an antioxidant is a com-
pound or varieties that decrease or stops the oxidation of
another compound (Go¨c¸er et al., 2013).
Among a plenty of natural product verities, polyphenols
are the most abundant antioxidants (Scalbert et al., 2005a).
Current evidence strongly facilitates a participation of
polyphenols to the protection of heart illnesses and malig-
nancies, and indicates a role in the protection of neurodegen-
erative illnesses and type 2 diabetes (Scalbert et al., 2005b).
Hesperidin (30,5,7-trihydroxy-40-methoxy-flavanone-7-rham
noglucoside) is a member of the flavanone group of flavo-
noids and its deglycosylated forms are known as hesperetin.
A number of studies have examined the antioxidant or radi-
cal scavenging (Cho, 2006) and anticancer properties
(Roohbakhsh et al., 2015; Jeong et al., 1999) of hesperidin
and hesperetin. Studies suggested that hesperidin is inactive
or only moderately active (Garg et al., 2001; Wilmsen
et al., 2005). In contrast, hesperetin was shown to have
potent antioxidant effects (Hirata et al., 2005). In addition,
reports suggest that hesperetin is a potent inhibitor of the
human cervical cancer cell lines (Alshatwi et al., 2013). In
a view of enlightened standpoint, we have decided to select
hesperetin a as nodule of the rationale design which is con-
nected to the diverse triazole core (Patel and Park, 2014)
known to inhibit angiogenesis, a tool for stopping tumor
growth and metastasis (Kallander et al., 2005). As cancers
figure among the leading causes of fatalities and death rate
globally, with approximately 14 million new cases and
8.2 million melanoma related fatalities in 2012 (World
Cancer Report, 2014; WHO, 2015) including its direct corre-
lation with ROS, we have decided to prepare new substituted
benzyl-1,2,3-triazolyl flavanone derivatives with an aim to
obtain newer generation of antioxidant and anticancer
agents.2. Experimental
Commercially available chemicals and solvents were used
without purification or after distillation and treatment with
drying agents. Hesperidin was purchased from Sigma–Aldrich
Company Ltd. Reactions were monitored by thin-layer chro-
matography (TLC) on pre-coated silica gel plates (Kieselgel
60 F254, Merck) and visualized by UV254 light. Shimadzu
8400-S FT-IR spectrophotometer was used to obtain FT-IR
spectra of the title compounds. NMR spectra were taken using
a Bruker AVANCE III 400 instrument (1H NMR, 400 MHz;
13C NMR, 100 MHz). 1H NMR spectra are represented as fol-
lows: chemical shift, multiplicity (s = singlet, d = doublet,
t = triplet, q = quartet, m = multiplet), integration, and cou-
pling constant (J) in Hertz (Hz). 1H NMR and 13C NMR
chemical shifts are reported relative to CDCl3 as internal stan-
dard. Purity of compounds was determined by elemental anal-
yses performed using CHN analyzer.2.1. Synthesis of 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-
chroman-4-one (2)
A mixture of 1 (5.7 mmol) and H2SO4 (10 mL) in anhydrous
CH3OH (280 mL) was stirred at 60 C for 9 h, and ethyl acet-
ate (1.2 L) was then added at 20 C. The solution was washed
with H2O (420 mL), and dried (Na2SO4). Evaporation
afforded pale-yellow powder. The crude product was dissolved
in acetone (70 mL) and added dropwise (60 min) to a stirred
mixture of H2O/acetic acid (150:1, 700 mL) at 95 C. The
slurry was cooled to 45 C and the product filtered and dried
in vacuo to give 2: Yield: 89%, M.p. 222–224 C.
2.2. Synthesis of 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-
7-(prop-2-ynyloxy)chroman-4-one (4)
Propargyl bromide (3) (0.5 mmol) was dropwise added to a
solution of compound 2 (1 mmol) in acetonitrile and the reac-
tion mixture was stirred at 75 C for 4 h. Reaction was moni-
tored by TLC and the crude product was subjected to column
chromatography (Hexane: EtOAc) to give pure compound 4.
Yield: 58%. IR (KBr) cm1: 3365 (OH), 1627 (C‚O), 1438
(Ar). 1H NMR (CDCl3, 400 MHz): d 12.18 (s, 1H, OH), 9.11
(s, 1H, OH), 6.91–6.86 (m, 3H, ArAH), 6.38 (d, J= 2.2 Hz,
1H), 6.21 (d, J= 2.3 Hz, 1H), 5.47 (dd, J= 2.6, 12.2 Hz,
1H), 5.22 (s, 2H, OCH2), 3.82 (s, 3H, OCH3), 3.19 (dd,
J= 12.7, 17.2 Hz,1H, 3-H trans), 2.61 (dd, J= 2.8, 17.2 Hz,
1H, 3-H cis), 2.29 (s, 1H, CH). 13C NMR (CDCl3,
100 MHz): d 186.4, 165.7, 163.3, 161.5, 157.6, 154.2, 135.1,
119.0, 111.9, 110.1, 102.4, 98.5, 93.8, 84.2, 80.3, 78.7, 66.5
(OCH3), 64.4 (OCH2), 45.6. EMI–MS (m/z): 341.69 (M
+).
Anal. Calcd. for C19H16O6: C, 67.05; H, 4.74. Found: C,
67.22; H, 4.59.
Pharmacologically active 1,2,3-triazolyl hesperetins 1592.3. General procedure for the synthesis of compounds 6a-6s
Appropriate benzyl derivatives (0.65 mmol) were sonicated at
35 C in the presence of a solution of NaN3 (0.8 mmol) in
DMF (15 mL) and the progress of the reaction was monitored
by TLC. After completion, CuSO45H2O (0.12 mmol) and
sodium ascorbate (0.30 mmol) as well as intermediate 4
(0.5 mmol) were added and reaction was allowed to stir at
room temperature for another 3 h. After completion, mixture
was filtered, and solvent was evaporated under reduced pres-
sure. The crude thus obtained was extracted with dichloro-
methane (3  40 mL) and the combined organic layer was
dried over sodium sulfate and purified through column chro-
matography (MeOH:CHCl3) to afford the final product 6a-
6s in 40–85% yield.
2.3.1. 7-((1-benzyl-1H-1,2,3-triazol-4-yl)methoxy)-5-hydroxy-
2-(3-hydroxy-4-methoxyphenyl)chroman-4-one (6a)
Yield: 53%. M.p. 189–191 C. IR (KBr) cm1: 3391 (OH),
1644 (C‚O), 1560 (C‚C, triazole), 1466 (CAN, triazole),
1450 (Ar), 1403 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.12 (s, 1H, OH), 9.18 (s, 1H, OH), 7.62 (s,
1H, triazole-H), 7.41–7.34 (m, 5H, ArAH), 6.95–6.87 (m,
3H, ArAH), 6.30 (d, J= 2.2 Hz, 1H), 6.18 (d, J= 2.3 Hz,
1H), 5.51 (dd, J= 2.6, 12.2 Hz, 1H), 5.29 (s, 2H, CH2), 5.17
(s, 2H, OCH2), 3.77 (s, 3H, OCH3), 3.21 (dd, J= 12.7,
17.2 Hz,1H, 3-H trans), 2.65 (dd, J= 2.8, 17.2 Hz, 1H, 3-H
cis). 13C NMR (CDCl3, 100 MHz): d 182.2, 180.9, 165.3,
163.1, 161.6, 160.6, 157.4, 154.8, 146.2 (C-4, triazole), 141.5,
137.1, 135.3, 132.9 (C-5, triazole), 130.7, 129.1, 125.4, 124.6,
123.8, 119.9, 110.1, 106.5, 98.2, 93.8, 66.2 (OCH3), 64.3
(OCH2), 54.6 (NACH2). EMI–MS (m/z): 474.67 (M
+). Anal.
Calcd. for C26H23N3O6: C, 65.95; H, 4.90; N, 8.87. Found:
C, 66.03; H, 4.98; N, 8.96.
2.3.2. 7-((1-(2-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one (6b)
Yield: 44%. M.p. 161–163 C. IR (KBr) cm1: 3360 (OH),
1650 (C‚O), 1553 (C‚C, triazole), 1472 (CAN, triazole),
1444 (Ar), 1409 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.06 (s, 1H, OH), 9.12 (s, 1H, OH), 7.56 (s,
1H, triazole-H), 7.44–7.31 (m, 4H, ArAH), 6.97–6.89 (m,
3H, ArAH), 6.42 (d, J= 2.3 Hz, 1H), 6.18 (d, J= 2.2 Hz,
1H), 5.39 (dd, J= 2.7, 12.4 Hz, 1H), 5.23 (s, 2H, CH2), 5.11
(s, 2H, OCH2), 3.71 (s, 3H, OCH3), 3.15 (dd, J= 12.6,
17.1 Hz,1H, 3-H trans), 2.71 (dd, J= 2.9, 17.3 Hz, 1H, 3-H
cis). 13C NMR (CDCl3, 100 MHz): d 181.1, 179.2, 166.8,
164.6, 162.0, 159.7, 156.2, 153.0, 145.8 (C-4, triazole), 142.6,
138.5, 136.8, 132.7 (C-5, triazole), 131.2, 128.0, 126.8, 125.1,
124.5, 118.2, 111.8, 107.4, 98.6, 94.9, 67.1 (OCH3), 65.0
(OCH2), 55.1 (NACH2). EMI–MS (m/z): 492.29 (M
+). Anal.
Calcd. for C26H22FN3O6: C, 63.54; H, 4.51; N, 8.55. Found:
C, 63.67; H, 4.37; N, 8.42.
2.3.3. 7-((1-(3-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one (6c)
Yield: 41%. M.p. 173–175 C. IR (KBr) cm1: 3402 (OH),
1636 (C‚O), 1567 (C‚C, triazole), 1459 (CAN, triazole),
1437 (Ar), 1415 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.18 (s, 1H, OH), 9.06 (s, 1H, OH), 7.68 (s,1H, triazole-H), 7.42–7.33 (m, 4H, ArAH), 6.94–6.86 (m,
3H, ArAH), 6.36 (d, J= 2.4 Hz, 1H), 6.24 (d, J= 2.4 Hz,
1H), 5.45 (dd, J= 2.5, 12.3 Hz, 1H), 5.36 (s, 2H, CH2), 5.06
(s, 2H, OCH2), 3.83 (s, 3H, OCH3), 3.27 (dd, J= 12.5,
17.3 Hz,1H, 3-H trans), 2.77 (dd, J= 2.7, 17.1 Hz, 1H, 3-H
cis). 13C NMR (CDCl3, 100 MHz): d 182.4, 180.7, 166.6,
163.3, 162.8, 160.4, 157.6, 153.1, 146.4 (C-4, triazole), 142.8,
137.3, 135.9, 133.0 (C-5, triazole), 130.5, 128.8, 125.6, 124.8,
123.6, 118.4, 110.3, 107.6, 99.8, 93.6, 66.4 (OCH3), 64.8
(OCH2), 54.4 (NACH2). EMI–MS (m/z): 492.63 (M
+). Anal.
Calcd. for C26H22FN3O6: C, 63.54; H, 4.51; N, 8.55. Found:
C, 63.69; H, 4.63; N, 8.45.
2.3.4. 7-((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one (6d)
Yield: 49%. M.p. 182–184 C. IR (KBr) cm1: 3380 (OH),
1645 (C‚O), 1561 (C‚C, triazole), 1467 (CAN, triazole),
1451 (Ar), 1404 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.13 (s, 1H, OH), 9.19 (s, 1H, OH), 7.63 (s,
1H, triazole-H), 7.40–7.30 (m, 4H, ArAH), 6.96–6.85 (m,
3H, ArAH), 6.31 (d, J= 2.4 Hz, 1H), 6.19 (d, J= 2.2 Hz,
1H), 5.52 (dd, J= 2.5, 12.4 Hz, 1H), 5.30 (s, 2H, CH2), 5.18
(s, 2H, OCH2), 3.78 (s, 3H, OCH3), 3.22 (dd, J= 12.6,
17.3 Hz,1H, 3-H trans), 2.66 (dd, J= 2.7, 17.1 Hz, 1H, 3-H
cis). 13C NMR (CDCl3, 100 MHz): d 181.3, 179.4, 165.5,
164.8, 161.4, 159.5, 156.4, 154.6, 145.1 (C-4, triazole), 141.9,
138.7, 136.4, 133.5 (C-5, triazole), 131.4, 129.3, 126.6, 125.3,
124.3, 119.7, 111.6, 106.7, 99.4, 94.7, 67.3 (OCH3), 65.2
(OCH2), 55.0 (NACH2). EMI–MS (m/z): 492.75 (M
+). Anal.
Calcd. for C26H22FN3O6: C, 63.54; H, 4.51; N, 8.55. Found:
C, 63.41; H, 4.39; N, 8.40.
2.3.5. 7-((1-(2-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one (6e)
Yield: 51%. M.p. 176–178 C. IR (KBr) cm1: 3356 (OH),
1651 (C‚O), 1554 (C‚C, triazole), 1473 (CAN, triazole),
1445 (Ar), 1410 (N‚N, triazole), 750 (CACl). 1H NMR
(CDCl3, 400 MHz): d 12.07 (s, 1H, OH), 9.13 (s, 1H, OH),
7.57 (s, 1H, triazole-H), 7.43–7.32 (m, 4H, ArAH), 6.98–6.90
(m, 3H, ArAH), 6.43 (d, J= 2.3 Hz, 1H), 6.13 (d,
J= 2.3 Hz, 1H), 5.40 (dd, J= 2.6, 12.3 Hz, 1H), 5.24 (s,
2H, CH2), 5.12 (s, 2H, OCH2), 3.72 (s, 3H, OCH3), 3.16 (dd,
J= 12.7, 17.2 Hz,1H, 3-H trans), 2.72 (dd, J= 2.9, 17.2 Hz,
1H, 3-H cis). 13C NMR (CDCl3, 100 MHz): d 181.7, 180.5,
165.7, 163.5, 161.2, 160.2, 157.8, 154.4, 146.6 (C-4, triazole),
141.7, 138.9, 135.5, 132.3 (C-5, triazole), 130.3, 129.5, 125.8,
124.0, 123.4, 119.5, 110.5, 106.9, 98.8, 93.4, 66.8 (OCH3),
64.1 (OCH2), 55.3 (NACH2). EMI–MS (m/z): 508.78 (M
+).
Anal. Calcd. for C26H22ClN3O6: C, 61.48; H, 4.37; N, 8.27.
Found: C, 61.36; H, 4.51; N, 8.40.
2.3.6. 7-((1-(3-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one (6f)
Yield: 43%. M.p. 193–195 C. IR (KBr) cm1: 3410 (OH),
1637 (C‚O), 1568 (C‚C, triazole), 1460 (CAN, triazole),
1438 (Ar), 1416 (N‚N, triazole), 765 (CACl). 1H NMR
(CDCl3, 400 MHz): d 12.19 (s, 1H, OH), 9.07 (s, 1H, OH),
7.69 (s, 1H, triazole-H), 7.45–7.35 (m, 4H, ArAH), 6.93–6.88
(m, 3H, ArAH), 6.37 (d, J= 2.2 Hz, 1H), 6.25 (d,
J= 2.4 Hz, 1H), 5.46 (dd, J= 2.7, 12.2 Hz, 1H), 5.37 (s,
2H, CH2), 5.07 (s, 2H, OCH2), 3.84 (s, 3H, OCH3), 3.28 (dd,
160 B. Mistry et al.J= 12.5, 17.1 Hz,1H, 3-H trans), 2.78 (dd, J= 2.8, 17.3 Hz,
1H, 3-H cis). 13C NMR (CDCl3, 100 MHz): d 182.6, 179.6,
166.4, 164.4, 162.6, 160.0, 156.6, 153.3, 145.3 (C-4, triazole),
142.1, 137.5, 136.2, 132.5 (C-5, triazole), 131.6, 128.6, 126.4,
125.5, 124.7, 118.6, 111.4, 107.8, 98.4, 94.5, 67.5 (OCH3),
65.4 (OCH2), 54.2 (NACH2). EMI–MS (m/z): 508.72 (M
+).
Anal. Calcd. for C26H22ClN3O6: C, 61.48; H, 4.37; N, 8.27.
Found: C, 61.35; H, 4.29; N, 8.38.
2.3.7. 7-((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one (6g)
Yield: 52%. M.p. 165–167 C. IR (KBr) cm1: 3376 (OH),
1646 (C‚O), 1562 (C‚C, triazole), 1468 (CAN, triazole),
1452 (Ar), 1405 (N‚N, triazole), 778 (CACl). 1H NMR
(CDCl3, 400 MHz): d 12.14 (s, 1H, OH), 9.20 (s, 1H, OH),
7.64 (s, 1H, triazole-H), 7.41–7.31 (m, 4H, ArAH), 6.95–6.89
(m, 3H, ArAH), 6.32 (d, J= 2.2 Hz, 1H), 6.20 (d,
J= 2.4 Hz, 1H), 5.53 (dd, J= 2.7, 12.2 Hz, 1H), 5.31 (s,
2H, CH2), 5.19 (s, 2H, OCH2), 3.79 (s, 3H, OCH3), 3.23 (dd,
J= 12.5, 17.1 Hz,1H, 3-H trans), 2.67 (dd, J= 2.8, 17.3 Hz,
1H, 3-H cis). 13C NMR (CDCl3, 100 MHz): d 182.1, 179.8,
166.2, 163.7, 162.4, 159.3, 157.2, 153.5, 146.8 (C-4, triazole),
142.3, 137.7, 135.7, 132.7 (C-5, triazole), 130.1, 128.4, 125.0,
124.2, 123.2, 118.8, 110.7, 107.2, 99.6, 93.2, 66.9 (OCH3),
64.7 (OCH2), 54.1 (NACH2). EMI–MS (m/z): 508.96 (M
+).
Anal. Calcd. for C26H22ClN3O6: C, 61.48; H, 4.37; N, 8.27.
Found: C, 61.62; H, 4.32; N, 8.34.
2.3.8. 7-((1-(2-bromobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one (6h)
Yield: 47%. M.p. 156–158 C. IR (KBr) cm1: 3362 (OH),
1652 (C‚O), 1555 (C‚C, triazole), 1474 (CAN, triazole),
1446 (Ar), 1411 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.08 (s, 1H, OH), 9.14 (s, 1H, OH), 7.58 (s,
1H, triazole-H), 7.44–7.33 (m, 4H, ArAH), 6.97–6.86 (m,
3H, ArAH), 6.44 (d, J= 2.4 Hz, 1H), 6.14 (d, J= 2.3 Hz,
1H), 5.41 (dd, J= 2.5, 12.4 Hz, 1H), 5.25 (s, 2H, CH2), 5.13
(s, 2H, OCH2), 3.73 (s, 3H, OCH3), 3.17 (dd, J= 12.6,
17.3 Hz,1H, 3-H trans), 2.73 (dd, J= 2.7, 17.1 Hz, 1H, 3-H
cis). 13C NMR (CDCl3, 100 MHz): d 181.5, 180.3, 165.9,
164.2, 161.0, 159.1, 156.8, 154.2, 145.5 (C-4, triazole), 141.8,
138.2, 136.9, 133.9 (C-5, triazole), 131.8, 129.7, 126.2, 125.7,
124.9, 119.3, 111.2, 106.1, 98.0, 94.3, 67.7 (OCH3), 65.6
(OCH2), 55.5 (NACH2). EMI–MS (m/z): 553.55 (M
+). Anal.
Calcd. for C26H22BrN3O6: C, 56.53; H, 4.01; N, 7.61. Found:
C, 56.38; H, 4.13; N, 7.50.
2.3.9. 7-((1-(3-bromobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-
5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one (6i)
Yield: 42%. M.p. 186–188 C. IR (KBr) cm1: 3415 (OH),
1638 (C‚O), 1569 (C‚C, triazole), 1461 (CAN, triazole),
1439 (Ar), 1417 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.20 (s, 1H, OH), 9.08 (s, 1H, OH), 7.70 (s,
1H, triazole-H), 7.42–7.34 (m, 4H, ArAH), 6.94–6.85 (m,
3H, ArAH), 6.38 (d, J= 2.3 Hz, 1H), 6.26 (d, J= 2.2 Hz,
1H), 5.47 (dd, J= 2.6, 12.3 Hz, 1H), 5.38 (s, 2H, CH2), 5.08
(s, 2H, OCH2), 3.85 (s, 3H, OCH3), 3.29 (dd, J= 12.7,
17.2 Hz,1H, 3-H trans), 2.79 (dd, J= 2.9, 17.2 Hz, 1H, 3-H
cis). 13C NMR (CDCl3, 100 MHz): d 182.8, 180.1, 165.1,
163.9, 161.1, 160.9, 157.0, 154.9, 146.1 (C-4, triazole), 141.6,
137.4, 135.1, 132.1 (C-5, triazole), 130.9, 129.2, 125.1, 124.4,123.9, 119.1, 110.9, 106.3, 99.2, 93.0, 66.6 (OCH3), 64.9
(OCH2), 55.7 (NACH2). EMI–MS (m/z): 553.23 (M
+). Anal.
Calcd. for C26H22BrN3O6: C, 56.53; H, 4.01; N, 7.61. Found:
C, 56.65; H, 4.14; N, 7.70.
2.3.10. 7-((1-(4-bromobenzyl)-1H-1,2,3-triazol-4-yl)
methoxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-
4-one (6j)
Yield: 50%. M.p. 175–177 C. IR (KBr) cm1: 3394 (OH),
1647 (C‚O), 1563 (C‚C, triazole), 1469 (CAN, triazole),
1453 (Ar), 1406 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.15 (s, 1H, OH), 9.21 (s, 1H, OH), 7.65 (s,
1H, triazole-H), 7.40–7.32 (m, 4H, ArAH), 6.96–6.87 (m,
3H, ArAH), 6.33 (d, J= 2.3 Hz, 1H), 6.21 (d, J= 2.2 Hz,
1H), 5.54 (dd, J= 2.6, 12.3 Hz, 1H), 5.32 (s, 2H, CH2), 5.20
(s, 2H, OCH2), 3.80 (s, 3H, OCH3), 3.24 (dd, J= 12.7,
17.2 Hz,1H, 3-H trans), 2.68 (dd, J= 2.9, 17.2 Hz, 1H, 3-H
cis). 13C NMR (CDCl3, 100 MHz): d 181.2, 179.9, 166.7,
164.0, 162.2, 159.0, 156.9, 153.7, 145.7 (C-4, triazole), 142.5,
137.9, 135.8, 132.8 (C-5, triazole), 131.1, 128.9, 126.9, 125.2,
124.8, 118.9, 111.1, 107.0, 98.9, 94.1, 67.9 (OCH3), 65.8
(OCH2), 54.3 (NACH2). EMI–MS (m/z): 553.62 (M
+). Anal.
Calcd. for C26H22BrN3O6: C, 56.53; H, 4.01; N, 7.61. Found:
C, 56.61; H, 4.09; N, 7.52.
2.3.11. 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((1-(2-
methylbenzyl)-1H-1,2,3-triazol-4-yl)methoxy)chroman-4-one
(6k)
Yield: 46%. M.p. 160–162 C. IR (KBr) cm1: 3353 (OH),
1653 (C‚O), 1556 (C‚C, triazole), 1475 (CAN, triazole),
1447 (Ar), 1412 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.09 (s, 1H, OH), 9.15 (s, 1H, OH), 7.59 (s,
1H, triazole-H), 7.43–7.30 (m, 4H, ArAH), 6.98–6.88 (m,
3H, ArAH), 6.45 (d, J= 2.4 Hz, 1H), 6.15 (d, J= 2.4 Hz,
1H), 5.42 (dd, J= 2.7, 12.2 Hz, 1H), 5.26 (s, 2H, CH2), 5.14
(s, 2H, OCH2), 3.74 (s, 3H, OCH3), 3.18 (dd, J= 12.5,
17.3 Hz,1H, 3-H trans), 2.74 (dd, J= 2.8, 17.1 Hz, 1H, 3-H
cis), 1.94 (s, 3H, CH3).
13C NMR (CDCl3, 100 MHz): d
181.4, 180.0, 165.0, 163.2, 161.3, 160.7, 157.1, 153.9, 146.3
(C-4, triazole), 141.4, 137.2, 136.6, 133.2 (C-5, triazole),
130.8, 128.2, 125.3, 124.9, 123.7, 118.7, 110.2, 107.1, 99.1,
93.9, 67.0 (OCH3), 64.5 (OCH2), 54.4 (NACH2), 20.4. EMI–
MS (m/z): 488.27 (M+). Anal. Calcd. for C27H25N3O6: C,
66.52; H, 5.17; N, 8.62. Found: C, 66.65; H, 5.25; N, 8.50.
2.3.12. 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((1-(4-
methylbenzyl)-1H-1,2,3-triazol-4-yl)methoxy)chroman-4-
one (6l)
Yield: 48%. M.p. 153–155 C. IR (KBr) cm1: 3408 (OH),
1639 (C‚O), 1570 (C‚C, triazole), 1462 (CAN, triazole),
1440 (Ar), 1418 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.21 (s, 1H, OH), 9.09 (s, 1H, OH), 7.71 (s,
1H, triazole-H), 7.45–7.36 (m, 4H, ArAH), 6.93–6.84 (m,
3H, ArAH), 6.36 (d, J= 2.2 Hz, 1H), 6.27 (d, J= 2.3 Hz,
1H), 5.48 (dd, J= 2.5, 12.3 Hz, 1H), 5.30 (s, 2H, CH2), 5.09
(s, 2H, OCH2), 3.86 (s, 3H, OCH3), 3.30 (dd, J= 12.6,
17.1 Hz,1H, 3-H trans), 2.80 (dd, J= 2.7, 17.3 Hz, 1H, 3-H
cis), 1.83 (s, 3H, CH3).
13C NMR (CDCl3, 100 MHz): d
182.0, 179.7, 166.9, 164.1, 162.9, 160.5, 156.7, 154.7, 145.0
(C-4, triazole), 141.2, 138.6, 136.7, 132.6 (C-5, triazole),
130.6, 129.4, 125.5, 124.7, 123.5, 119.0, 111.5, 106.2, 98.7,
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MS (m/z): 488.67 (M+). Anal. Calcd. for C27H25N3O6: C,
66.52; H, 5.17; N, 8.62. Found: C, 66.61; H, 5.08; N, 8.70.
2.3.13. 2-((4-((5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-
oxochroman-7-yloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)
benzonitrile (6m)
Yield: 40%. M.p. 185–187 C. IR (KBr) cm1: 3367 (OH),
1648 (C‚O), 1564 (C‚C, triazole), 1470 (CAN, triazole),
1454 (Ar), 1407 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.16 (s, 1H, OH), 9.22 (s, 1H, OH), 7.66 (s,
1H, triazole-H), 7.41–7.32 (m, 4H, ArAH), 6.95–6.88 (m,
3H, ArAH), 6.34 (d, J= 2.3 Hz, 1H), 6.22 (d, J= 2.3 Hz,
1H), 5.55 (dd, J= 2.6, 12.4 Hz, 1H), 5.33 (s, 2H, CH2), 5.21
(s, 2H, OCH2), 3.81 (s, 3H, OCH3), 3.25 (dd, J= 12.6,
17.1 Hz,1H, 3-H trans), 2.69 (dd, J= 2.8, 17.1 Hz, 1H, 3-H
cis). 13C NMR (CDCl3, 100 MHz): d 182.9, 180.2, 165.2,
163.4, 162.7, 159.8, 157.3, 154.5, 146.5 (C-4, triazole), 142.7,
138.8, 135.6, 133.8 (C-5, triazole), 131.3, 128.5, 126.7, 125.9,
124.0, 119.8, 117.3, 110.4, 106.4, 99.3, 93.7, 66.5 (OCH3),
65.3 (OCH2), 55.2 (NACH2). EMI–MS (m/z): 499.31 (M
+).
Anal. Calcd. for C27H22N4O6: C, 65.05; H, 4.45; N, 11.24.
Found: C, 64.97; H, 4.33; N, 11.12.
2.3.14. 4-((4-((5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-
oxochroman-7-yloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)
benzonitrile (6n)
Yield: 43%. M.p. 178–180 C. IR (KBr) cm1: 3374 (OH),
1654 (C‚O), 1557 (C‚C, triazole), 1476 (CAN, triazole),
1448 (Ar), 1413 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.10 (s, 1H, OH), 9.16 (s, 1H, OH), 7.60 (s,
1H, triazole-H), 7.44–7.35 (m, 4H, ArAH), 6.97–6.87 (m,
3H, ArAH), 6.46 (d, J= 2.4 Hz, 1H), 6.16 (d, J= 2.2 Hz,
1H), 5.43 (dd, J= 2.7, 12.4 Hz, 1H), 5.27 (s, 2H, CH2), 5.15
(s, 2H, OCH2), 3.75 (s, 3H, OCH3), 3.19 (dd, J= 12.7,
17.2 Hz,1H, 3-H trans), 2.75 (dd, J= 2.9, 17.2 Hz, 1H, 3-H
cis). 13C NMR (CDCl3, 100 MHz): d 181.6, 179.5, 166.5,
164.3, 161.5, 159.6, 156.0, 153.2, 145.2 (C-4, triazole), 142.9,
137.4, 135.2, 132.4 (C-5, triazole), 131.5, 129.6, 126.5, 125.4,
124.6, 118.5, 119.7, 111.3, 107.3, 98.5, 94.4, 67.8 (OCH3),
64.6 (OCH2), 54.5 (NACH2). EMI–MS (m/z): 499.62 (M
+).
Anal. Calcd. for C27H22N4O6: C, 65.05; H, 4.45; N, 11.24.
Found: C, 64.98; H, 4.54; N, 11.33.
2.3.15. 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((1-
(3-methoxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)
chroman-4-one (6o)
Yield: 50%. M.p. 164–166 C. IR (KBr) cm1: 3405 (OH),
1640 (C‚O), 1571 (C‚C, triazole), 1463 (CAN, triazole),
1441 (Ar), 1419 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.22 (s, 1H, OH), 9.10 (s, 1H, OH), 7.72 (s,
1H, triazole-H), 7.42–7.31 (m, 4H, ArAH), 6.94–6.88 (m,
3H, ArAH), 6.40 (d, J= 2.3 Hz, 1H), 6.28 (d, J= 2.4 Hz,
1H), 5.49 (dd, J= 2.5, 12.3 Hz, 1H), 5.31 (s, 2H, CH2), 5.10
(s, 2H, OCH2), 3.87 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.31
(dd, J= 12.5, 17.3 Hz,1H, 3-H trans), 2.81 (dd, J= 2.7,
17.3 Hz, 1H, 3-H cis). 13C NMR (CDCl3, 100 MHz): d
182.7, 179.3, 165.4, 163.6, 162.5, 160.3, 157.5, 153.4, 146.7
(C-4, triazole), 141.1, 138.0, 136.5, 133.6 (C-5, triazole),
130.4, 128.3, 125.7, 124.5, 123.3, 119.6, 110.6, 107.5, 99.9,
93.5, 67.6 (OCH3), 66.2, 64.4 (OCH2), 55.4 (NACH2). EMI–MS (m/z): 504.66 (M+). Anal. Calcd. for C27H25N3O7: C,
64.41; H, 5.00; N, 8.35. Found: C, 64.30; H, 4.88; N, 8.47.
2.3.16. 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((1-(4-
methoxybenzyl)-1H-1,2,3-triazol-4-yl)methoxy)chroman-4-one
(6p)
Yield: 53%. M.p. 157–159 C. IR (KBr) cm1: 3359 (OH),
1641 (C‚O), 1565 (C‚C, triazole), 1471 (CAN, triazole),
1455 (Ar), 1408 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.17 (s, 1H, OH), 9.23 (s, 1H, OH), 7.67 (s,
1H, triazole-H), 7.40–7.33 (m, 4H, ArAH), 6.96–6.86 (m,
3H, ArAH), 6.35 (d, J= 2.4 Hz, 1H), 6.23 (d, J= 2.3 Hz,
1H), 5.56 (dd, J= 2.7, 12.2 Hz, 1H), 5.34 (s, 2H, CH2), 5.22
(s, 2H, OCH2), 3.82 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.26
(dd, J= 12.6, 17.2 Hz,1H, 3-H trans), 2.70 (dd, J= 2.8,
17.2 Hz, 1H, 3-H cis). 13C NMR (CDCl3, 100 MHz): d
181.0, 180.4, 163.3, 164.5, 161.7, 159.4, 156.3, 154.3, 145.4
(C-4, triazole), 142.0, 137.6, 136.3, 132.2 (C-5, triazole),
130.2, 129.8, 125.9, 124.3, 123.1, 118.3, 111.9, 106.6, 98.3,
94.6, 66.3 (OCH3), 65.9, 65.5 (OCH2), 54.7 (NACH2). EMI–
MS (m/z): 504.36 (M+). Anal. Calcd. for C27H25N3O7: C,
64.41; H, 5.00; N, 8.35. Found: C, 64.32; H, 5.09; N, 8.27.
2.3.17. 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((1-(3-
(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)methoxy)
chroman-4-one (6q)
Yield: 44%. M.p. 194–196 C. IR (KBr) cm1: 3420 (OH),
1655 (C‚O), 1558 (C‚C, triazole), 1477 (CAN, triazole),
1449 (Ar), 1414 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.11 (s, 1H, OH), 9.17 (s, 1H, OH), 7.61 (s,
1H, triazole-H), 7.43–7.34 (m, 4H, ArAH), 6.98–6.89 (m,
3H, ArAH), 6.47 (d, J= 2.2 Hz, 1H), 6.17 (d, J= 2.4 Hz,
1H), 5.44 (dd, J= 2.6, 12.4 Hz, 1H), 5.28 (s, 2H, CH2), 5.16
(s, 2H, OCH2), 3.76 (s, 3H, OCH3), 3.20 (dd, J= 12.7,
17.1 Hz,1H, 3-H trans), 2.76 (dd, J= 2.9, 17.3 Hz, 1H, 3-H
cis). 13C NMR (CDCl3, 100 MHz): d 182.5, 180.8, 165.6,
163.8, 162.3, 160.1, 157.7, 153.6, 146.9 (C-4, triazole), 142.2,
138.1, 135.4, 133.4 (C-5, triazole), 131.7, 128.7, 126.3, 125.6,
124.9, 124.4, 119.4, 110.8, 106.0, 99.5, 93.3, 66.1 (OCH3),
65.7 (OCH2), 55.6 (NACH2). EMI–MS (m/z): 541.32 (M
+).
Anal. Calcd. for C27H22F3N3O6: C, 59.89; H, 4.10; N, 7.76.
Found: C, 59.96; H, 4.23; N, 7.89.
2.3.18. 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((1-(4-
(trifluoromethyl)benzyl)-1H-1,2,3-triazol-4-yl)methoxy)
chroman-4-one (6r)
Yield: 43%.M.p. 190–192 C. IR (KBr) cm1: 3411 (OH), 1642
(C‚O), 1572 (C‚C, triazole), 1464 (CAN, triazole), 1442
(Ar), 1420 (N‚N, triazole). 1H NMR (CDCl3, 400 MHz): d
12.23 (s, 1H, OH), 9.11 (s, 1H, OH), 7.73 (s, 1H, triazole-H),
7.45–7.32 (m, 4H, ArAH), 6.93–6.83 (m, 3H, ArAH), 6.41 (d,
J= 2.3 Hz, 1H), 6.29 (d, J= 2.2 Hz, 1H), 5.50 (dd, J= 2.5,
12.3 Hz, 1H), 5.32 (s, 2H, CH2), 5.05 (s, 2H, OCH2), 3.88 (s,
3H, OCH3), 3.32 (dd, J= 12.6, 17.3 Hz,1H, 3-H trans), 2.82
(dd, J= 2.8, 17.1 Hz, 1H, 3-H cis). 13C NMR (CDCl3,
100 MHz): d 181.8, 179.1, 166.0, 164.7, 161.9, 159.2, 156.1,
154.1, 145.6 (C-4, triazole), 141.3, 137.8, 135.0, 132.0 (C-5, tri-
azole), 131.9, 129.0, 126.1, 125.8, 125.3, 124.2, 118.1, 111.7,
107.7, 98.1, 94.8, 67.4 (OCH3), 64.2 (OCH2), 54.9 (NACH2).
EMI–MS (m/z): 541.68 (M+). Anal. Calcd. for C27H22F3N3O6:
C, 59.89; H, 4.10; N, 7.76. Found: C, 59.77; H, 4.02; N, 7.64.
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nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)chroman-4-one (6s)
Yield: 45%. M.p. 177–179 C. IR (KBr) cm1: 3389 (OH),
1642 (C‚O), 1566 (C‚C, triazole), 1465 (CAN, triazole),
1443 (Ar), 1407 (N‚N, triazole). 1H NMR (CDCl3,
400 MHz): d 12.07 (s, 1H, OH), 9.24 (s, 1H, OH), 7.63 (s,
1H, triazole-H), 7.43–7.35 (m, 4H, ArAH), 6.95–6.86 (m,
3H, ArAH), 6.48 (d, J= 2.4 Hz, 1H), 6.19 (d, J= 2.3 Hz,
1H), 5.57 (dd, J= 2.7, 12.4 Hz, 1H), 5.35 (s, 2H, CH2), 5.23
(s, 2H, OCH2), 3.71 (s, 3H, OCH3), 3.21 (dd, J= 12.5,
17.2 Hz,1H, 3-H trans), 2.72 (dd, J= 2.7, 17.3 Hz, 1H, 3-H
cis). 13C NMR (CDCl3, 100 MHz): d 182.3, 180.6, 165.8,
163.0, 162.1, 160.8, 157.9, 153.8, 146.0 (C-4, triazole), 142.4,
138.3, 136.1, 133.1 (C-5, triazole), 130.0, 128.0, 125.2, 124.1,
123.0, 119.2, 110.0, 106.8, 99.7, 93.1, 67.2 (OCH3), 65.9
(OCH2), 55.8 (NACH2). EMI–MS (m/z): 519.60 (M
+). Anal.
Calcd. for C26H22N4O8: C, 60.23; H, 4.28; N, 10.81. Found:
C, 60.36; H, 4.15; N, 10.92.
2.4. Biological assays
2.4.1. DPPH free radical scavenging assay
Free radicals exercise deleterious role in biological systems and
in foods and hence radical scavenging activities are very useful.
Various chemical reactions running in the biological systems
usually furnish free radicals which are responsible to cause
damage to the building block of biologics such as DNA and
lipids. Reduction of a stable free radical, 2,2-diphenyl-
1-picrylhydrazyl is the base of DPPH antioxidant bioassay. It
has an odd electron which exerts a maximum absorption band
of 517 nm (deep violet color) in ethanol. The DPPH bioassay
is the widely used and acceptable method for inspecting the free
radical scavenging efficacy of the intended compound. Such sub-
stances donate a hydrogen atom when it mixes with the DPPH
thereby introducing its reduced congener, diphenylpicrylhy-
drazine (nonradical) with the loss of violet color.
In the present study, DPPH bioassay was adopted to screen
6a-s for their in vitro antioxidant potencies. The results of this
bioassay screenings were presented in the form of the percentage
of radical scavenging antioxidant activity (RSA%) of each sub-
stance. The investigation of the DPPH radical scavenging activ-
ity was operated according to the methodology described by
Brand-Williams et al. (1995). A stable free radical, 2,2-
diphenyl-1-picrylhydrazyl was allowed to react with 6a-s in
methanol solvent as 20 lL quantities of titled compounds were
mixed up with 180 lL of DPPH in MeOH. These titled com-
pounds donated hydrogen in this mixing thereby carried out
reduction ofDPPHandhence a change in the colorwas observed
from deep violet to light yellow at 517 nm after 25 min of reac-
tion using a UV–Visible spectrophotometer (Perkin Elmer).
The lank reading was also performed using the mixture of
methanol (20 lL) and sample (180 lL of DPPH). Ascorbic acid
served as a control drug in this assay and its solution was pre-
pared upon mixing methanol (20 lL) and DPPH radical solu-
tion (180 lL). The results of this bioassay, RSA% (the radical
scavenging activity in percentage) were determined according
to Mensor et al. (2001) as described in below equation.
% Scavenging ¼ Absorbance of blank Absorbance of test
Absorbance of blank
 100A plot between concentration of test compounds and %
scavenging introduced IC50 levels in the presence of Ascorbic
acid as standard.
2.4.2. ABTS radical scavenging assay
The ABTS+ radical cation scavenging efficacies of the test
compounds were determined according to the method
described earlier (Re et al., 1999). Mixing of an equal amount
of 7 mM ABTS+ (2,20-azino-bis(3-ethylbenzothiazoline-6-sul
fonic acid)) stock solution with 2.45 mM potassium persulfate
stock solution produces the ABTS+ cation. The mixture was
kept in dark place at 0 C temperature for 12 h and ABTS
solution was diluted with MeOH so that it gives UV absorp-
tion value of 0.700 (±0.200) at the 734 nm. The 1000 lL stock
solutions of titled compounds 3a-j were established upon dis-
solving them in MeOH and further dilutions furnish 100 lL,
10 lL, 1 lL, and 0.1 lL of quantities of samples. 180 lL solu-
tions of compounds to be evaluated and 20 lL of the ABTS
solution was mixed in 96 well plates in dark place which were
then incubated for 10 min to measure UV absorption at
734 nm. Mixture of 180 lL ABTS and 20 lL mL methanol
was used as a control determination, whereas ascorbic acid
was used as a reference drug. The UV absorption data repre-
sented the radical scavenging rates which give the correspond-
ing IC50 levels for the test compounds.
The scavenging capability of ABTS+ radical was calcu-
lated using the following equation:
% Scavenging ¼ Absorbance of blank Absorbance of test
Absorbance of blank
 1002.5. In vitro anticancer bioassay
The test compounds 6a-s were checked for their in vitro anti-
cancer potential against cervical cancer cell lines (HeLa and
CaSki) and an ovarian cancer cell line (SK-OV-3) and cyto-
toxic action against Madin Darby canine kidney (MDCK)
cells which were purchased from American Type Culture
Collection (ATCC). All the cell lines were well maintained
in a humidified cell culture incubator in the presence of
5% of CO2 at 32 C temperature. Dulbecco’s Modified
Eagle’s Medium (DMEM) and RPMI-1640 Medium supple-
mented with 10% of fetal Bovine Serum (FBS) and 1% of
Antibiotic–Antimycotic solution (100) were used for HeLa,
CaSki, SK-OV-3 and MDCK cell growth respectively.
DMEM, RPMI-1640, trypsin–EDTA, Antibiotic–Antimy-
cotic Solution 100 and FBS were purchased from Welgene
(150-Seongseo Industrial complex Bukro, Dalseogu, Daegu,
704–948 Republic of Korea).
In the 96 well plates, all cancer cell lines (HeLa, CaSki and
SK-OV-3) and a non-cancer cell line (MDCK) were seeded
and plates were concentrated as 2  104 cells per well plate.
Cancerous cells were allowed to grow for 1 day initially and
after that the 96 well plates were washed twice with phosphate
buffer saline (PBS). DMEM and RPMI-1640 medium con-
tained trypsin–EDTA were used to dilute HeLa, CaSki, SK-
OV-3 and MDCK cells up to 5  103 level which was used
for the infection followed by placing of 10 lL of compound
quantities and 90 lL of cell solution onto the 96 well plates
in which HeLa, CaSki, SK-OV-3 and MDCK cells were
Table 1 Screening results of DPPH and ABTS radical
scavenging activity of 6a-s.
No. R IC50 lM± SD
a
DPPH ABTS
6a H 56.45 ± 2.339 8.545 ± 0.545
6b 2-F 52.12 ± 1.568 12.645 ± 0.733
6c 3-F 44.96 ± 2.034 15.645 ± 2.280
6d 4-F 37.34 ± 3.397 13.534 ± 0.471
6e 2-Cl 43.85 ± 1.645 17.532 ± 1.325
6f 3-Cl 71.27 ± 1.143 19.542 ± 0.843
6g 4-Cl 41.90 ± 0.754 33.582 ± 2.422
6h 2-Br 41.63 ± 1.533 16.608 ± 0.356
6i 3-Br 41.57 ± 0.854 14.338 ± 1.098
6j 4-Br 35.89 ± 1.643 14.092 ± 0.313
6k 2-CH3 38.09 ± 0.741 13.445 ± 2.188
6l 4-CH3 33.21 ± 2.675 12.621 ± 0.235
6m 2-CN 83.57 ± 0.456 34.952 ± 2.032
6n 4-CN 73.55 ± 2.534 18.135 ± 0.134
6o 3-OCH3 30.75 ± 1.965 9.118 ± 1.002
6p 4-OCH3 33.17 ± 1.245 17.742 ± 0.424
6q 3-CF3 36.79 ± 2.645 21.433 ± 1.955
6r 4-CF3 35.28 ± 1.258 18.621 ± 1.456
6s 4-NO2 66.20 ± 0.423 39.356 ± 0.644
Ascorbic acid – 12.72 ± 0.274 5.0925 ± 0.2090
a The results are average of triplicate analysis.
Pharmacologically active 1,2,3-triazolyl hesperetins 163grown the previous day. 0.1 lL, 1 lL, 10 lL and 100 lL con-
centrations of the test compounds were used in 96 well plates
for the analysis with three replicates of observations. Infected
plates were incubated in CO2 incubator for a period of 48 h.
After incubation the medium was removed and washed twice
with PBS buffer. After that, 70% of acetone was added to fix
the cells and was incubated for 1 h at 4 C temperature. After
incubation, solvent was removed and plates were dried in an
oven at 60 C temperature. The dried plates were overnight
incubated with 100 lL of SRB (0.4 mg/L) followed by SRB
removal and washing thrice with 1% of acetic acid and dried
again under hot air oven at 60 C. Microscopic observation
was carried out to determine the morphology of the cells
and after this observation the SRB strain was dissolved with
10 mM of Tris base and incubated overnight (Adaramoye
et al., 2011; Mistry et al., 2015). Spectrophotometric data
were recorded at 510 nm to calculate the inhibition concentra-
tion of 50% (IC50) and cytotoxic concentration of 50%
(CC50).
3. Results and discussion
3.1. Chemistry
Titled compounds 6a-s were synthesized via efficient reaction
sequences as described in Scheme 1. Hesperidin (1) was sub-
jected to hydrolysis in the presence of sulfuric acid in methanol
to give hesperetin 2 (Seitz and Wingard, 1987). Nucleophilic
substitution reaction of 2 with propargyl bromide (3) yielded
intermediate 4. Desired benzyl halides were diazotized in acidic
conditions and then treated with sodium azide to construct
corresponding azides (5a-s) Jin et al., 2014. CuSO45H2O
and sodium ascorbate in DMF were utilized for the
azide–alkyne cycloaddition through click chemistry between
aromatic azides (5a-s) and intermediate 4 to furnish final
1,2,3-triazole based hesperetin analogs 6a-s in reasonably good
yields. Structural elucidation using 1H NMR, 13C NMR and
mass spectrometry was in good accordance with assumed
structures. Newer compounds gave C, H and N analyses
within 0.4% points from the theoretical values, i.e. in
acceptable range.Scheme 1 Synthesis of substituted benzyl-13.2. Pharmacology
3.2.1. Antioxidant activities
DPPH and ABTS+ scavenging bioassay are the most common
spectrophotometric methods to inspect the antioxidant power
of the tested molecules. These free radicals interact with mole-
cules subjected for testing which are capable to reduce the stable
DPPH radical to the yellow colored diphenylpicrylhydrazine via
donating a hydrogen due to the formation of the nonradical
form,DPPH-H, during the reaction. To evaluate the free radical
scavenging activity of 6a-s, a DPPH assay was performed and
the results are expressed in terms of IC50 value (concentration
required to inhibit 50% of the radicals) as summarized in,2,3-triazolyl hesperetin derivatives 6a-s.
Table 2 Screening results of activity of 6a-s against cervical
cancer cell lines.
No. R IC50 lM± SD
a IC50 lM± SD
a CC50 lM± SD
a
HeLa CaSki MDCK
6a H 39.645 ± 1.234 52.822 ± 1.088 302.8 ± 2.348
6b 2-F 17.754 ± 0.754 27.644 ± 0.159 289.2 ± 1.573
6c 3-F 27.333 ± 0.674 22.535 ± 1.321 204.3 ± 1.907
6d 4-F 18.272 ± 0.544 15.453 ± 0.153 257.4 ± 0.394
6e 2-Cl 25.138 ± 1.556 33.274 ± 0.222 301.2 ± 2.571
6f 3-Cl 44.051 ± 0.986 31.546 ± 1.130 238.6 ± 3.422
6g 4-Cl 27.923 ± 0.578 42.832 ± 1.245 287.6 ± 2.575
6h 2-Br 33.456 ± 1.644 12.721 ± 0.256 198.9 ± 1.700
6i 3-Br 61.631 ± 1.463 15.547 ± 1.096 233.3 ± 0.207
6j 4-Br 38.574 ± 0.761 19.146 ± 0.134 261.4 ± 3.772
6k 2-CH3 34.258 ± 2.003 16.046 ± 1.097 334.7 ± 2.792
6l 4-CH3 37.731 ± 0.445 19.543 ± 0.146 329.1 ± 4.250
6m 2-CN 89.643 ± 0.613 67.634 ± 2.189 179.8 ± 1.415
6n 4-CN 69.354 ± 1.856 54.445 ± 1.097 237.1 ± 3.634
6o 3-OCH3 56.753 ± 0.534 14.925 ± 0.078 290.9 ± 0.856
6p 4-OCH3 61.083 ± 1.344 29.842 ± 2.269 312.2 ± 2.980
6q 3-CF3 102.754 ± 1.521 27.329 ± 1.267 238.5 ± 5.931
6r 4-CF3 74.521 ± 0.634 49.531 ± 0.129 273.3 ± 4.436
6s 4-NO2 46.982 ± 0.744 77.841 ± 0.251 306.7 ± 1.162
a The results are average of triplicate analysis.
164 B. Mistry et al.Table 1. New flavanone derivatives 6a-s possessed 30.75
± 1.965  83.57 ± 0.456 lM and 9.118 ± 1.002  39.356
± 0.644 lMof IC50 levels inDPPHandABTSbioassay, respec-
tively and can be comparable to ascorbic acid exerting 12.72
± 0.274 lM (DPPH) and 5.0925 ± 0.2090 lM (ABTS) of
IC50 levels. In general, titled scaffolds expressed encouraging
results against ABTS+ when compared to DPPH. It was
observed that types and position of electron withdrawing
(EWD) or electron donating (ED) substituent played an essen-
tial role in delivering corresponding radical scavenging sensitiv-
ities. For example, molecules bearing EWD presented
significant antioxidant power against DPPH radical, for exam-
ple an analog 6o carrying 3-OCH3 group demonstrated 30.75
± 1.965 lM of IC50 level. Moreover, 6l bearing 4-CH3 as well
as 6p holding 4-OCH3 functionalities showed 33.21
± 2.675 lM and 33.17 ± 1.245 lM of IC50 levels, respectively
against DPPH. Overall data suggested that to achieve antioxi-
dant activity against DPPH the nature of substituent was
important than its position on the phenyl ring. However, in case
of scaffolds carrying EWD halogen(s) groups, those with para-
substitution were more active than their meta- and ortho-
congeners. For example, 6j with 4-Br group expressed 35.89
± 1.643 lM of IC50 toward DPPH
, whereas 6h (2-Br) and 6i
(3-Br) showed nearly 41 lMof IC50. Compound 6awith no sub-
stituent present on the phenyl ring displayed weak antioxidant
power against DPPH, and the fact was suggestive of the impor-
tance of placing appropriate substituent on the phenyl ring to
achieve anticipated radical scavenging potencies. It was noticed
that increasing number of halogen atoms resulted into the scaf-
folds exercising positively influenced antioxidant effects, as 6q
and 6r with CF3 group had 36.79 ± 2.645 lM and 35.28
± 1.258 lM of IC50 levels, respectively and were higher than
the antioxidant power of remaining halogen based analogs.
Among EWD and ED based flavanones, antioxidant activity
order can be presented as OCH3 > CH3 and CF3 >
Br > F> Cl > NO2 > CN, respectively.
The ABTS+ assay is based on a single electron transfer, the
ABTS radical-cation decolorization, which is based on the
reduction of ABTS+ radicals by antioxidants. To evaluate
the free radical scavenging activity of 6a-s, ABTS assay was
performed and the results are expressed in terms of IC50 value
(concentration required to inhibit 50% of the radicals) as sum-
marized in Table 1. Similar to DPPH assay, compound 6o car-
rying 3-OCH3 group had most potent scavenging activity
against ABTS+ with 9.118 ± 1.002 lM of IC50, and was com-
parable to that of control ascorbic acid at 5.0925 ± 0.2090 lM.
In fact, the position of the substituent had no influence of the
corresponding ABTS+ scavenging efficacies of 6a-s. Analogs
6b with 2-F and 6l with 4-CH3 expressed 12.645 ± 0.733 lM
and 12.621 ± 0.235 lM of IC50 levels, respectively and were
the second most active group of molecules against ABTS+.
Furthermore, it was found that analogs with EWD fluorine
(6d) and ED methyl (6k) groups had contributed at a larger
extent in presenting ABTS+ sensitivities with IC50 levels
nearby 13 lM. Bromine bearing scaffolds (6i-6j) demonstrated
13.445 ± 2.188 lM  14.338 ± 1.098 lM of IC50 levels and
can be comparable to the most active molecules in the series
tested against ABTS+. Opposite to DPPH assay, it was
observed that increasing the number of halogen atoms had neg-
ative influence of the corresponding ABTS+ scavenging effica-
cies of the result scaffolds as 6q and 6r had weak antioxidant
effects with 21.433 ± 1.955 lM and 18.621 ± 1.456 lM ofIC50 levels. Among EWD and ED based flavanone derivatives,
the activity order can be placed as F > Br > Cl > CF3 > -
CN>NO2 and OCH3 > CH3, respectively.
3.2.2. Anticancer activities
Analogs 6a-s were screened in the three cancer cell lines panel
consisting of HeLa and CaSki (cervical) as well as SK-OV-3
(ovarian). End point determinations were made with a protein
binding dye, sulforhodamine B (SRB) called SRB assay and
the results of anticancer screening tests for 6a-s against cervical
cancer cell lines are summarized in Table 2.
Overall results suggested that nature and position of the
substituents had considerable impact of the anticancer effects
of tested molecules. Compounds holding EWD halogen atoms
were more active against HeLa cell line than their ED based
congeners. For example, 6b (2-F) and 6d (4-F) expressed
17.754 ± 0.754 lM and 18.272 ± 0.544 lM of IC50 levels,
respectively and were the most active anticancer agents against
HeLa among all tested. These two molecules had tolerable
cytotoxicity toward MDCK cell line with 289.2 ± 1.573 lM
and 257.4 ± 0.394 lM of CC50 levels. The fact was suggestive
of the importance of fluorine for potency against HeLa cell
line, but it was noticed that increasing the number of fluorine
atoms diminished the activity of corresponding scaffolds, for
example 6q and 6r had 102.754 ± 1.521 lM and 74.521
± 0.634 lM of IC50 levels against HeLa, respectively. More-
over, analogs 6e and 6g with chlorine group presented
25.138 ± 1.556 and 27.923 ± 0.578 lM of IC50 levels, and
301.2 ± 2.571 and 287.6 ± 2.575 lM of CC50 levels, respec-
tively. The data suggested that ortho- and para-position has
reasonable influence on the corresponding anticancer action
of the resultant EWD based molecules against HeLa cell line.
In addition, halogen based molecules holding meta-
substitution were found poorly active against HeLa, as scaf-
folds 6c (3-F), 6f (3-Cl) and 6i (3-Br) displayed 27.333
Pharmacologically active 1,2,3-triazolyl hesperetins 165± 0.674 lM, 44.051 ± 0.986 lM and 61.631 ± 1.463 lM of
IC50 levels, respectively. Among ED based flavanones, an ana-
log with ortho-methyl substituent (6k) exerted 34.258
± 2.003 lM of IC50, but had significantly remarkable cytotox-
icity toward MDCK cell line at 334.7 ± 2.792 lM of CC50. In
fact, its para-congener (6l) also showed 37.731 ± 0.445 lM of
IC50 and can be considered to have desirable anticancer effects
against HeLa cell line. Overall among EWD and ED based fla-
vanones, anticancer effects against HeLa cell line can be
respectively placed as F > Cl > Br > NO2 > CF3 > CN
and CH3 > OCH3. The bioassay outcomes observed against
CaSki cell lines were irrespective of the nature of the sub-
stituent present on the phenyl ring of these flavanones. For
example, both EWD based 6d (4-F) and ED based 6l (4-
CH3) demonstrated 15.453 ± 0.153 and 19.543 ± 0.146 lM
of IC50 levels, respectively. Likewise to bioassay results against
HeLa cell line, increasing number of fluorine atom had nega-
tive effect on anticancer profiles of resultant analog, as CF3
based 6q and 6r displayed 27.329 ± 1.267 lM and 49.531
± 0.129 lM of IC50 levels, respectively. Furthermore, 6k with
2-CH3 functionality presented the best result as anticancer
molecule among all tested in the series with 16.046
± 1.097 lM of IC50, whereas 6o holding ED 3-OCH3 group
had 14.925 ± 0.078 lM of IC50. These results suggested that
ED group had achieved considerable attention in expressing
anticancer effects against CaSki cell line than those carrying
EWD groups unlike outcomes observed in SRB assay with
HeLa cell line. Furthermore, bromine based flavanone (6h)
appeared with lowest IC50 levels at 12.721 ± 0.256 lM, but
was found to exercise somewhat cytotoxicity at 198.9
± 1.700 lM. Another two bromine based molecules, 6i and
6j were succeeded to present 15.547 ± 1.096 lM and 19.146
± 0.134 lM of IC50 levels, respectively, which were at remark-
able level when compared to the potency of highly active mole-
cules in the series. Overall among EWD and ED based
flavanones, anticancer effects against CaSki cell line can beTable 3 Screening results of activity of 6a-s against ovarian
cancer cell line.
No. R IC50 lM± SD
a CC50 lM± SD
a
SK-OV-3 MDCK
6a H 61.651 ± 2.681 302.8 ± 2.348
6b 2-F 54.239 ± 1.923 289.2 ± 1.573
6c 3-F 36.610 ± 1.270 204.3 ± 1.907
6d 4-F 77.541 ± 1.456 257.4 ± 0.394
6e 2-Cl 47.229 ± 0.731 301.2 ± 2.571
6f 3-Cl 36.792 ± 0.542 238.6 ± 3.422
6g 4-Cl 56.873 ± 2.801 287.6 ± 2.575
6h 2-Br 43.665 ± 2.439 189.9 ± 1.700
6i 3-Br 39.120 ± 1.239 233.3 ± 0.207
6j 4-Br 64.542 ± 0.671 261.4 ± 3.772
6k 2-CH3 59.875 ± 2.099 334.7 ± 2.792
6l 4-CH3 56.438 ± 1.542 329.1 ± 4.250
6m 2-CN 78.541 ± 0.218 179.8 ± 1.415
6n 4-CN 95.346 ± 0.911 237.1 ± 3.634
6o 3-OCH3 41.479 ± 0.334 290.9 ± 0.856
6p 4-OCH3 47.580 ± 2.002 312.2 ± 2.980
6q 3-CF3 33.259 ± 1.534 238.5 ± 5.931
6r 4-CF3 49.561 ± 0.678 273.3 ± 4.436
6s 4-NO2 65.115 ± 2.541 306.7 ± 1.162
a The results are average of triplicate analysis.respectively placed as Br > F> Cl > CF3 > CN>NO2
and 2-CH3 > 3-OCH3 > 4-CH3 > 4-OCH3.
Analogs 6a-s were tested to inspect their in vitro inhibitory
efficacies against ovarian cancer cell line SK-OV-3 and the
results of anticancer screening tests for 6a-s are summarized
in Table 3. Although, the activity profiles seen for 6a-s against
SK-OV-3 were weak when compared to those observed against
cervical cancer cell lines, still the activity against SK-OV-3 was
appreciable in terms of constructing detailed SAR analysis, as
unlike above bioassay results, compounds 6q bearing highly
electronegative EWD 3-CF3 group had 33.259 ± 1.534 lM
of IC50, 238.5 ± 5.931 lM of CC50, which was very remark-
able. These data implied that increasing number of halogen
atoms may help to promote anticancer potential of the resul-
tant molecules against ovarian cancer cell line. In addition,
6o holding ED 3-OCH3 expressed 41.479 ± 0.334 lM of
IC50, 290.9 ± 0.856 lM of CC50 and was also found to have
high anticancer effects against SK-OV-3. It was also found
that anticancer results of 6a-s against SK-OV-3 had reversed
than those observed against cervical cancer cell line in terms
of position of substituents. For example, meta-position for
EWD based molecules was found beneficial to exert anticancer
effects against SK-OV-3, as 6c (3-F), 6f (3-Cl) and 6i (3-Br)
had 36.610 ± 1.270 lM, 36.792 ± 0.542 lM and 39.120
± 1.239 lM of IC50 levels, respectively than that of their
ortho- and para-substituted congeners at >43 lM. However,
in case of ED methyl carrying molecules, compound holding
para-substitution was observed to have better sensitivity in
inhibiting SK-OV-3, as 6l showed 56.438 ± 1.542 lM of
IC50 when compared to that of 6k (2-CH3) at 59.875
± 2.099 lM. Furthermore, unsubstituted phenyl ring was
found to yield better results against SK-OV-3 than molecules
holding NO2 and CN functionalities, as 6a had 61.651
± 2.681 lM of IC50, whereas 6m, 6n and 6s displayed
78.541 ± 0.218 lM, 95.346 ± 0.911 lM and 65.115
± 2.541 lM of IC50 levels, respectively. Overall among
EWD and ED based flavanones, anticancer effects against
SK-OV-3 cell line can be respectively placed as CF3 > Cl >
F> Br > NO2 > CN and OCH3 > CH3.4. Conclusion
Copper-catalyzed azide–alkyne cycloaddition yielded 1,2,3-
triazole core connecting a natural product flavanone hes-
peretin and substituted phenyls via click chemistry. With an
aim to discover semi-synthetic flavanones with antioxidant
and anticancer effects, titled scaffolds 6a-s were screened for
their DPPH and ABTS+ scavenging effects and cancerous
cell inhibitory effects against cervical (HeLa and CaSki) and
ovarian (SK-OV-3) cancer cell lines. From the bioassay out-
comes it was noticed that nature and position of the EWD
and ED substituents had remarkable effects. Molecules bear-
ing ED groups demonstrated strong sensitivities in scavenging
both DPPH and ABTS radicals and inhibiting CaSki cell line,
whereas, those holding EWD groups presented excellent
results against HeLa cell lines. Both EWD and ED based
molecules exercised similar action against ovarian cancer cell
line. In general, all the tested flavanone based 1,2,3-triazoles
displayed good pharmacological potential and can be a tool
to develop further set of highly potent antioxidant and anti-
cancer agents.
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